LDL/HDL Ratio in Women: From the Pill to After Menopause

The numerator of this number is your LDL cholesterol, the cholesterol that can accumulate in the artery wall; the denominator is your HDL cholesterol, the cholesterol carried back to the liver. No separate tube of blood is drawn for it: the laboratory divides two values that were already on your report and prints the outcome as a single figure without a unit. What makes the ratio distinctive in women sits in the denominator.

Oestrogen stimulates the production of HDL particles. Women in their reproductive years therefore carry a markedly higher HDL on average than men of the same age, and a larger denominator makes every fraction smaller. At an identical LDL your outcome lands lower than your partner's, without anything having been said about your artery wall. Work it through: an LDL of 3.6 mmol/l alongside an HDL of 1.8 mmol/l gives 2.0, while the very same LDL alongside an HDL of 1.1 mmol/l lands at 3.3. One numerator, two entirely different conclusions.

That numerator is meanwhile the most fragile part of the sum. In most laboratories your LDL is not measured but estimated: total cholesterol, reduced by the HDL and by a fixed share of the triglycerides. The estimate assumes triglycerides stay modest. Take an oestrogen preparation by mouth and they climb instead, so the estimated LDL drops away when it should not. The cholesterol/HDL ratio does not carry that flaw, because both of its values are determined directly.

Do not confuse the two either. The cholesterol/HDL ratio puts total cholesterol above the line, and for that one the NVKC publishes a limit of 5, preferably below 3.5. For the LDL/HDL ratio the NVKC publishes no limit; the 3 that is often quoted is an international rule of thumb without a Dutch source, and that is why this page shows no reference value.

A single rule of thumb for both sexes sounds even-handed, but it lands unevenly. Because women's HDL sits higher on average, the often quoted limit of 3 is in practice a far gentler test for you than for a man. You can sit comfortably below 3 with an LDL your own doctor would want to raise with you. That is the heart of the objection to this number in women: it reassures at exactly the moment there is something to discuss.

On top of that comes the arithmetic blindness of any fraction. Take two women who both land on 3.0. The first has 3.0 mmol/l LDL alongside 1.0 mmol/l HDL. The second has 4.5 mmol/l LDL alongside 1.5 mmol/l HDL. Their figure is identical, yet the second carries half as much harmful cholesterol again. It is that absolute quantity which settles into the artery wall across decades.

Then the transition. In the years around menopause you lose the oestrogenic protection from two sides at once: LDL climbs while HDL often slips a little. With almost any other cause only one half of the fraction moves; here they move together. The consequence is that the ratio rises more steeply than the LDL or the HDL on their own, and a woman used to years of favourable results can see a very different number within a few years. That is no personal failure and certainly no diagnosis; it is a hormonal shift becoming visible in your lipids.

And then this: no guideline sets a target for this fraction. The European ESC/EAS guideline steers on the LDL itself, with non-HDL cholesterol and ApoB as secondary goals; the Dutch NHG CVRM standard steers on LDL and non-HDL. If either of those appears on your report, let it weigh more heavily than any fraction. Non-HDL also counts the VLDL and remnant particles that are entirely absent from this ratio, and ApoB counts the number of harmful particles rather than their cargo. Both tell you something this division cannot.

You do not order this ratio separately; it arrives automatically as soon as a lipid panel has determined the LDL and the HDL. So the question is when such a panel yields anything meaningful, and in women that depends more on life stage than on age.

Your cycle is not a serious obstacle here: cholesterol values drift slightly with it, but not enough to overturn a result. Hormone use counts for far more. Starting or stopping the pill, switching to another preparation, or beginning hormone therapy around menopause changes your profile within a few months. So do not test in the first weeks afterwards, and record with every result which preparation you were using at the time.

Fasting weighs more heavily here than for the individual cholesterol values, because your LDL is derived from the triglycerides. Above roughly 4.5 mmol/l that derivation is no longer valid and the outcome says nothing. Pregnancy also lifts the whole lipid profile substantially; a panel belongs some months after delivery. Wait a few weeks after an infection or surgery as well, and when comparing two results allow for the natural noise of five to ten percent on the LDL.

A newly unfavourable profile deserves an explanation before your diet takes the blame. An underactive thyroid raises LDL and occurs considerably more often in women than in men, so have a TSH included in the first round. Poorly controlled diabetes, kidney and liver disease, heavy alcohol use and a range of medicines can equally explain the picture.

Each life stage moves the ratio in its own direction. In the reproductive years without a hormone preparation, LDL is on average lower than in men of the same age and oestrogen keeps HDL higher, so the ratio runs structurally low, even with an LDL that deserves attention. On a combined pill with oral oestrogen, HDL usually rises, although some progestogens push it down, and triglycerides rise alongside, which makes the calculated LDL less reliable. Hormone therapy taken as tablets lowers LDL and raises HDL, because the oestrogen passes through the liver first, while the higher triglycerides distort the numerator; by patch or gel the profile barely changes, because the skin route bypasses the liver. In perimenopause LDL begins to rise and HDL may slip slightly, so the ratio climbs faster than the LDL alone. After menopause LDL sits structurally higher and HDL on average slightly lower, and the ratio shifts towards the male level.

Always have your result assessed by a doctor, together with your individual values and your full risk profile.